Sangamo Therapeutics Inc (SGMO)
OTCHealth CareBiotechnologySnapshot 2026-09-04
$0.07+4.22%
Close 2026-07-28 · 1-day change
OTCHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SGMO
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 34.6 | 39.6 | 57.8 | 176.2 | 111.3 | 110.7 | 118.2 | 102.4 | 84.5 | 36.6 | 19.4 | 39.5 | 45.9 | 24.1 | 21.7 | 10.3 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 36.6 | 19.4 | 39.5 | 45.9 | 24.1 | 21.7 | 10.3 |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 113.2 | 112.7 | 111.5 | 234.1 | 249.9 | 230.8 | 180.6 | 145.9 | 114.9 | 65.7 | 65.6 | 67.2 | 57.0 | 37.0 | 31.7 | 32.1 |
| Operating Income | (123.6) | (121.2) | (104.0) | (274.0) | (201.3) | (183.3) | (129.6) | (105.2) | (77.2) | (56.4) | (72.6) | (46.9) | (26.8) | (26.7) | (22.2) | (35.8) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest & Investment Income | — | 1.3 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | — | — | — | — | — | — | — | — | — | — | — | — | 0.4 | 0.1 | (0.1) | 0.1 |
| EBT, Incl. Unusual Items | (124.0) | (123.5) | (98.1) | (262.9) | (191.8) | (178.0) | (120.8) | (95.4) | (68.9) | (54.6) | (71.7) | (46.4) | — | — | — | — |
| Income Tax Expense | — | (0.6) | (0.2) | (5.1) | 0.4 | 0.3 | 0.3 | 0.0 | (0.0) | (0.0) | (0.0) | (5.7) | 0.0 | — | — | — |
| Net Income | ||||||||||||||||
| Minority Interest | — | — | — | 0.0 | 0.0 | (0.0) | (0.1) | (0.2) | (0.6) | — | — | — | — | — | — | — |
| Net Income | (123.3) | (122.9) | (97.9) | (257.8) | (192.3) | (178.3) | (121.0) | (95.2) | (68.3) | (54.6) | (71.7) | (40.7) | (26.4) | (26.6) | (22.3) | (35.8) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.32) | (0.44) | (0.49) | (1.48) | (1.25) | (1.23) | (0.90) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (0.32) | (0.44) | (0.49) | (1.48) | (1.25) | (1.23) | (0.90) | — | — | — | — | — | — | — | — | — |
| Revenue per Share | 0.09 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 389.6 | 280.2 | 201.7 | 174.4 | 154.3 | 144.6 | 134.4 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 389.6 | 280.2 | 201.7 | 174.4 | 154.3 | 144.6 | 134.4 | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (117.3) | (98.9) | (258.9) | (189.2) | (173.9) | (123.9) | (101.3) | (74.8) | (54.9) | (71.6) | (45.9) | (26.2) | (26.1) | (21.5) | (35.2) |
| EBIT | (123.6) | (121.2) | (104.0) | (274.0) | (201.3) | (183.3) | (129.6) | (105.2) | (77.2) | (56.4) | (72.6) | (46.9) | (26.8) | (26.7) | (22.2) | (35.8) |
| Effective Tax Rate | — | — | — | 1.9% | -0.2% | -0.2% | -0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 12.3% | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.